Please login to the form below
oral octreotide acetate
This page shows the latest oral octreotide acetate news and features for those working in and with pharma, biotech and healthcare.
Roche licenses Chiasma’s acromegaly drug in $595m deal
The licensing deal - valued at up to $595m - is for Octreolin (oral octreotide acetate), a drug candidate which which is currently in phase III testing for acromegaly and also in development ... Our oral octreotide has the potential to improve the
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- FDA approves Roche’s Actemra COVID-19 trial
- 3 ways to increase patient retention rates in clinical trials
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
PMHub
Frontera Group
Welcome to Frontera Group, where our agencies immerse you in the world of the patient...
Latest intelligence
- 3 ways to increase patient retention rates in clinical trials
- Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
Quick links
Infographics
